Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis

Meta-analysis of >87, 000 patients demonstrates that patients with invasive lobular carcinoma of the breast are far less likely to achieve pCR of the breast or axilla compared to their ductal counterparts, receive less BCS and more frequently return positive margins. BACKGROUND: Neoadjuvant chemotherapy (NACT) facilitates tumour downstaging, increases breast conserving surgery (BCS) and assesses tumour chemosensitivity. Despite clinicopathological differences in Invasive Ductal Carcinoma (IDC) and Invasive Lobular Carcinoma (ILC), decision making surrounding the use NACT does not take account of histological differences. AIM: To determine the impact NACT on pathological complete response (pCR), breast conserving surgery (BCS), margin status and axillary pCR in ILC and IDC. METHODS: A systematic review was performed in accordance with the PRISMA guidelines. Studies reporting outcomes among ILC and IDCs following NACT were identified. Dichotomous variables were pooled as odds ratios (ORs) with 95% confidence intervals_ (CI) using the Mantel-Haenszel method. P-values <0. 05 were statistically significant. RESULTS: 40 studies including 87, 303 (7596 ILC 8. 7%and 79, 708 IDC 91. 3%) patients were available for analysis. Mean age at diagnosis was 54. 9 vs. 50. 9 years for ILC and IDC, respectively. IDCs were significantly more likely to achieve pCR (22. 1% v 7. 4%, OR: 3. 03 95% CI 2. 5-3. 68 p < 0. 00001), axillary pCR (23. 6% vs. 13. 4%, OR: 2. 01 95% CI 1. 77-2. 28 p < 0. 00001) and receive BCS (45. 7% vs. 33. 3%, OR 2. 14 95% CI 1. 87-2. 45 p < 0. 00001) versus ILCs. ILCs were significantly more likely to have positive margins at the time of surgery (36% vs 13. 5%, OR 4. 84 95% CI 2. 88-8. 15 p < 0. 00001). CONCLUSION: This is the largest study comparing the impact of NACT among ILC and IDC with respect to pCR and BCS. ILC has different outcomes to IDC following NACT and incorporate it into treatment decisions and future clinical guidelines.